Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis.

Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis.
Cancer J. 2020 Mar/Apr;26(2):116-123
Authors: Routman DM, Chera BS, Gupta GP
Abstract
Oligometastasis represents an intermediate disease stage between localized and widely metastatic cancer. Efficient identification of patients with oligometastasis remains a barrier for accrual on clinical trials of oligometastasis-directed therapy. Here we review the prospect of circulating tumor DNA-based monitoring to promote sensitive, specific, and cost-efficient detection of cancer recurrence during posttreatment surveillance. Thus, an impetus for the development and implementation of clinical-grade circulating tumor DNA assays should be for the positive impact they will have on clinical investigations of oligometastasis-directed therapy.
PMID: 32205535 [PubMed - in process]

Source: Cancer Journal - February 29, 2020 Category: Cancer & Oncology Authors: Routman DM, Chera BS, Gupta GP Tags: Cancer J Source Type: research